



NDA 20-527/S-029

Wyeth-Ayerst
Attention: Joseph S. Sonk, Ph.D.
Assistant Vice President
Worldwide Regulatory Affairs
P.O. Box 8299
Philadelphia, PA 19101-8299

Dear Dr. Sonk:

Please refer to your supplemental new drug application dated August 23, 2002, received August 26, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Prempro™ (conjugated estrogens/medroxyprogesterone acetate tablets).

We acknowledge receipt of your submissions dated August 27 and September 27, 2002.

This "Changes Being Effected" supplemental new drug application provides for revisions in the text of the direction circular to include recently published information from the Women's Health Initiative (WHI) study and the American Cancer Society.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with the minor editorial revisions listed below.

In the **DESCRIPTION** section, the ™ symbol should be added to PREMPRO and the ® symbol should be added to PREMPHASE in the first two paragraphs.

The final printed labeling (FPL) must be identical, and include the minor editorial revisions indicated, to the draft labeling submitted on August 23, 2002. These revisions are terms of the approval of this application(s).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format-NDA (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-527/S-029." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kassandra Sherrod, R.Ph., Regulatory Project Manager, at (301) 827-4260.

Sincerely,

{See appended electronic signature page}

Daniel Shames, M.D.
Director
Division of Reproductive and Urologic Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Shelley Slaughter

11/27/02 09:51:02 AM

Shelley R. Slaughter, M.D., Ph.D. for Division Director Daniel
Shames, M.D.